Oral Semaglutide's Absorption Enhancer SNAC Disrupts Gut Bacteria and Triggers Inflammation
The absorption enhancer SNAC used in oral semaglutide significantly altered gut microbiota and triggered systemic inflammation in rats, potentially contributing to GI side effects.
Quick Facts
What This Study Found
SNAC absorption enhancer in oral semaglutide significantly disrupts gut microbiota and triggers systemic inflammation in rats, independent of semaglutide's effects.
Key Numbers
How They Did This
Preclinical study in Sprague Dawley rats over 21 days; three treatment groups (SEM, SNAC, SEM-SNAC) with microbiota analysis, metabolic profiling, and inflammatory marker assessment.
Why This Research Matters
If SNAC contributes to oral semaglutide's GI side effects, developing better absorption technologies could improve tolerability and reduce treatment discontinuation.
The Bigger Picture
Understanding excipient contributions to drug side effects is crucial for next-generation oral peptide formulations — the problem may be the delivery technology, not the drug itself.
What This Study Doesn't Tell Us
Animal model — rat gut microbiome differs from human; 21-day duration may not capture long-term adaptation; SEM dose may not perfectly model human exposure.
Questions This Raises
- ?Would alternative oral peptide delivery technologies avoid SNAC-related gut disruption?
- ?Do these findings translate to human oral semaglutide users?
Trust & Context
- Key Stat:
- SNAC drives gut disruption Absorption enhancer, not semaglutide, is a major contributor to microbiota perturbation and inflammation
- Evidence Grade:
- Preclinical animal study — important mechanistic finding but requires human validation.
- Study Age:
- Published 2026 in Journal of Controlled Release.
- Original Title:
- Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery.
- Published In:
- Journal of controlled release : official journal of the Controlled Release Society, 392, 114711 (2026)
- Authors:
- Ariaee, Amin, Noueihad, Karim, Hunter, Alex, Wignall, Anthony, Wardill, Hannah R, Davies, Maya, Prestidge, Clive A, Joyce, Paul
- Database ID:
- RPEP-14784
Evidence Hierarchy
Frequently Asked Questions
Why does oral semaglutide cause stomach problems?
This study suggests that SNAC, the absorption enhancer needed for the pill to work, disrupts gut bacteria and triggers inflammation — meaning the delivery technology, not just the drug, may contribute to GI side effects.
What is SNAC?
Salcaprozate sodium (SNAC) is a compound added to oral semaglutide (Rybelsus) that helps the drug get absorbed through the stomach lining. Without it, almost none of the semaglutide would reach the bloodstream.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14784APA
Ariaee, Amin; Noueihad, Karim; Hunter, Alex; Wignall, Anthony; Wardill, Hannah R; Davies, Maya; Prestidge, Clive A; Joyce, Paul. (2026). Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery.. Journal of controlled release : official journal of the Controlled Release Society, 392, 114711. https://doi.org/10.1016/j.jconrel.2026.114711
MLA
Ariaee, Amin, et al. "Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery.." Journal of controlled release : official journal of the Controlled Release Society, 2026. https://doi.org/10.1016/j.jconrel.2026.114711
RethinkPeptides
RethinkPeptides Research Database. "Gut microbiota perturbation and systemic inflammation are as..." RPEP-14784. Retrieved from https://rethinkpeptides.com/research/ariaee-2026-gut-microbiota-perturbation-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.